N/A Completed N=66

Physiologic Phacofluidics: Ghost Protocol

Cataract

Source: ClinicalTrials.gov NCT06904404 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2025

Primary outcomePrimary: Change in Early Post Operative Central Corneal Thickness — 623.9; 650.2 microns

Summary

The goal of this clinical trial is to investigate the early post-operative benefits of performing phacoemulsification at physiologic intraocular pressures. The main questions it aims to answer are: * Is there less post operative corneal edema? * Is there less post operative inflammation? * Is the post operative vision better? Participants will undergo phacoemulsification cataract surgery with either high or low IOP settings Researchers will compare post op corneal edema, inflammatory marker levels and vision

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Early Post Operative Central Corneal Thickness	623.9; 650.2	—
SECONDARY IL-IB From Aqueous Sample	0.6130; 0.6806	—

Eligibility Criteria

Inclusion Criteria

Patients without prior ocular surgery both eyes
Adult patients with visually significant cataract with WHO-World Health Organization NUC grade 2-3
First eye only undergoing uncomplicated cataract surgery
Unremarkable systemic history; controlled diabetes with HbA1c 2.04mm10
Age range 55-95

Exclusion Criteria

Prior ocular surgery including corneal refractive surgery, cataract surgery in fellow eye
Thin corneas ( 15 mins) with post-operative complications (IOP spike >30mmHg), severe punctate keratitis

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06904404). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.